Last year, @CancerCare provided 150,508 services to people diagnosed with cancer, caregivers and bereaved individuals. Our emotional, practical and financial support programs continued to offer help and hope to anyone affected by cancer. Learn more at cancercare.org.

Explore non-squamous non-small cell lung cancer #ClinicalStudy options through myTRIAList. Our study finder features plain-language study overview videos, including the TeliMET #NSCLC-04 study, that help make study information more accessible. Learn more: bit.ly/4A7BNfO

We brought the Long Island cancer community together for a free, fall-inspired afternoon of pumpkin painting, creativity, and connection. Explore more of our community programs: loom.ly/eViNF0w

Would you consider using AI to help find a cancer clinical trial? This month, CancerCare wants to hear your thoughts and experiences with AI tools to find #clinicaltrials. Share your perspective through our Question of the Month poll: cancercare.org/question

A @PioneerPolicy and @CancerCare study found that 340B hospitals spend an average of just 2.16% of operating expenses on charity care. Non-340B hospitals spend 2.82%. Why are hospitals receiving billions in discounts to help vulnerable patients providing less charity care? forbes.com/sites/sallypipes/…

Understanding #ClinicalTrials can feel overwhelming. Noelle Cloven, MD, from Texas Oncology, shares insights in the RAINFOL-03 study video on myTRIAList. Explore possible clinical trial options and learn more here: bit.ly/4ssM3wu #EndometrialCancer #CancerResearch

FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations fda.gov/drugs/resources-info…

NEWS: Today, FDA approved a new treatment for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. fda.gov/drugs/resources-info…

New in @Forbes: Sally Pipes cites research from Pioneer and @CancerCare finding 340B hospitals spent an average of 2.16% of operating expenses on charity care vs. 2.82% for non-340B hospitals. Read it here: bit.ly/4sdBqgK 🔒

#340B reform must be a priority to improve access to healthcare for cancer patients, according to Kim Czubaruk of @CancerCare in a new opinion. Congress should take action to improve 340B transparency and accountability so patients benefit. Read more in @RealClearHealth: realclearhealth.com/articles…

FDA has granted accelerated approval of an immunotherapy for adults with previously untreated stage II or III locally advanced rectal cancer whose tumors are dMMR or MSI-H. In a phase 2 study, almost three-fourths of patients did not need surgery, radiotherapy, or chemotherapy after a median follow-up of more than 2 years. For eligible patients, treatment may help avoid chemotherapy, radiation and surgery and their lasting effects. This is the 11th approval under the Commissioner’s National Priority Voucher pilot program.

📋 New post-transplant GvHD symptom tracker Record your symptoms and track changes over time with our downloadable tracker. 💻 Complete digitally 🖨️ Or print and fill it in by hand 👩‍⚕️ Share with your healthcare team to help identify patterns or changes. 🔗 Download the tracker here: bit.ly/4jfm4pG #GvHD Independently supported by Therakos. Funders are allowed no influence.

FDA approves an expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer fda.gov/drugs/resources-info…

Big news for bladder cancer patients! FDA just expanded approval of Anktiva with BCG for adults with BCG-unresponsive, high-grade papillary-only NMIBC — the first treatment approved for this group. This is a first, and that matters. Evidence from a closely related form of bladder cancer supported the approval. fda.gov/drugs/resources-info…

Proud to have our CEO @AnjeeDavis at the 2026 @MilkenInstitute Patient Advocacy Forum in Washington, DC, where she spoke on "Patient Advocacy in the Age of AI, Data, and Digital Trust" about keeping AI-enabled health information accurate, trusted, and grounded in lived experience. It was great to connect with fellow cancer advocates @JulieFleshman, CEO of @PanCAN, and Christine Verini, RPh, CEO of @CancerCare, who share our commitment to putting patients first. Thank you to the Milken Institute for bringing us together! 💙 Access to trustworthy information matters. Find colorectal cancer resources for patients and families at fightcrc.org/resources.

News: Today, the @FDA approved a maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer. fda.gov/drugs/resources-info…

Submit your questions to our Ambassadors! Do you have a question about living with acute myeloid leukemia (AML) or caring for someone with AML that you’d like to ask other patients, caregivers, or healthcare professionals? We’re hosting a Know AML Ambassadors Meeting on October 22, 2026, and we want to hear from you. This is your opportunity to submit questions about the experiences, challenges, or practical aspects of AML that you’d like our Ambassadors to discuss. Share your questions: - In the comments - By direct message - Anonymously via the form here: forms.cloud.microsoft/e/EYeH… Selected questions will be discussed in the meeting, and a recording will be shared on the Know AML website to support the wider AML community. #KnowAML #Leukemia #BloodCancer

Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL @EliLillyandCo investor.lilly.com/news-rele…

“A discount this big shouldn’t be a mystery.” A new @CancerCare & @PioneerPolicy study of nearly 4,000 hospitals finds that #340B hospitals spend less on charity care than hospitals that don’t participate in the program. This research reinforces the need for greater transparency in 340B to ensure the program serves patients. Read more: cancercare.org/press/release…

Join our partners @_KNOW_ALL this Wednesday for a free webinar on support for older adults living with ALL. Register here: webinar.know-alleukemia.com/…

New study I co-authored, released by @PioneerPolicy and @CancerCare : 340B hospitals spent 2.16% of operating expenses on charity care vs. 2.82% at non-340B hospitals. Patients deserve accountability. pioneerinstitute.org/who-ben…